Johnson & Johnson will not conduct local trials for a single-dose vaccine against COVID-19 in India, the Economic Times reported Tuesday, citing a company spokesman.
Although J&J has sought approval to conduct bridging trials in the country, the U.S. drugmaker said it would not have to do so now as India has lifted the request, the report said.
The company is researching how to speed up the availability of its vaccine in India, the Economic Times said.
J&J did not immediately respond to Reuters’ request for comment.
Also read: Mullet can import Modern’s COVID-19 vaccine; approval probably today